FIELD: biochemistry.
SUBSTANCE: invention relates to a method for treating multiple myeloma in a subject using an anti-CD38 antibody. Also disclosed is a composition for treating multiple myeloma, a kit for treating multiple myeloma in a subject with the CD38 antibody, combination for treating multiple myeloma in a subject with the CD38 antibody.
EFFECT: invention is capable to effectively treat multiple myeloma in a subject with the help of CD38 antibody.
46 cl, 13 dwg, 1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
COMPOSITIONS CONTAINING ANTIBODIES TO CD38 AND LENALIDOMIDE | 2013 |
|
RU2698911C2 |
COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
HUMAN ANTI-CD38-ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2402568C2 |
AGENT FOR TREATING MULTIPLE MYELOMA (MM) | 2016 |
|
RU2723047C2 |
HUMANIZED ANTIBODIES TO THE THOMSEN-FRIEDENREICH ANTIGEN | 2015 |
|
RU2699717C2 |
ANTI-CD38 ANTIBODY AND LENALTDOMID OR BORTEZOMIB FOR TREATING MULTIPLE MYELOMA AND NHL | 2011 |
|
RU2595839C2 |
DIAGNOSING AND TREATING MALIGNANT TUMOUR WITH USING ANTI-EREG ANTIBODY | 2007 |
|
RU2537245C2 |
ANTI-INTEGRIN ALPHA-2 ANTIBODIES AND USING THEM | 2011 |
|
RU2545401C2 |
Authors
Dates
2020-06-18—Published
2014-03-13—Filed